Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
908 Devices Q3 2025 Earnings Call - Near-Term Government Delays Weighed Against Record Low Adjusted EBITDA Loss
908 Devices reported third quarter 2025 revenue of $14 million, down 4% year over year but up 8% sequentially, driven by strong demand for FTIR devices, particularly the Explorer Gas Identification un...
- Q3 2025 revenue from continuing operations was $14 million, down 4% year over year but up 8% sequentially, driven by FTIR devices like the Explorer gas identification unit.
- The company shipped 176 devices in the quarter, growing the installed base 27% year over year to over 3,500 devices, with recurring revenue representing 36% of total revenue.
- Revenue from the U.S. state and local channel accounted for 47% of total revenue year-to-date, highlighting a strategic shift towards more predictable, run-rate business.
- +17 more takeaways
CEVA Q3 2025 Earnings Call - AI Licensing Drives Breakthrough Momentum and Record Connectivity Shipments
CEVA delivered a third quarter exceeding expectations, with $28.4 million in revenue and $0.11 non-GAAP EPS, propelled by substantial AI licensing wins and robust growth in wireless connectivity. The ...
- Q3 revenue of $28.4 million and non-GAAP EPS of $0.11, beating expectations.
- Microchip licensed CEVA's full NPU portfolio, validating CEVA's AI edge inference position.
- AI processor licensing contributed about one-third of Q3 licensing revenue, a new milestone.
- +17 more takeaways
Instacart Q3 2025 Earnings Call - Confident Growth Driven by Marketplace Strength and Enterprise Technology Expansion
Instacart’s Q3 2025 earnings call showcased a company not just weathering the online grocery storm but steering confidently into new growth avenues. CEO Chris Rogers, in his first call, emphasized Ins...
- Instacart’s marketplace orders rose 14% year-over-year to 83.4 million, driven by increased customer retention and order frequency.
- The enterprise platform, powering 350+ retailer e-commerce storefronts, is a core growth driver and differentiator beyond the marketplace.
- New AI Solutions launched to help retailers improve personalized shopping, smarter operations, and in-store intelligence with promising early demand.
- +17 more takeaways
Bitdeer 3Q 2025 Earnings Call - Rapid Bitcoin Mining Growth and Bold AI Infrastructure Expansion
Bitdeer reported a staggering 173.6% year-over-year revenue surge to $169.7 million in Q3 2025, fueled by a 273.1% jump in its self-mining hash rate, exceeding its 40 exahash per second target with 41...
- Bitdeer’s Q3 2025 revenue soared 173.6% year-over-year to $169.7 million, driven by surging Bitcoin mining operations.
- Self-mining hash rate jumped 273.1% year-over-year and crossed 41.2 exahash per second, surpassing the 2025 target of 40 EX/s.
- Gross profit rose sharply to $40.8 million with improved fleet-wide energy efficiency, bolstering margins to 24.1%.
- +13 more takeaways
EVgo Q3 2025 Earnings Call - Nearing Adjusted EBITDA Break-Even with Strong Network Growth and Operational Leverage
EVgo reported a solid Q3 2025 with $92 million in revenue, driven by record charging network revenues and nearly 4,600 operational stalls. The company is on track to achieve adjusted EBITDA break-even...
- EVgo delivered Q3 2025 total revenue of $92 million, a 37% YoY increase, with record charging network revenues of $56 million, up 33%.
- Operational stall count reached nearly 4,600, a 2.7x increase since end of 2021, with expectations for a large Q4 deployment surge.
- Company is approaching adjusted EBITDA break-even, anticipated in Q4 2025, marking a significant financial inflection point.
- +12 more takeaways
Townsquare Media Q3 2025 Earnings Call - Digital Growth Offsets Broadcast Declines Amid AI-Driven Traffic Drops
Townsquare Media delivered Q3 2025 results largely in line with guidance, with total net revenue at $106.8 million and adjusted EBITDA at $22 million. The company reinforced its transformation into a ...
- Townsquare's Q3 2025 net revenue ($106.8M) and adjusted EBITDA ($22M) met prior guidance despite macroeconomic headwinds.
- Digital revenues accounted for 55% of total net revenue in the first nine months of 2025, more than double the industry average, underscoring Townsquare’s successful digital transformation.
- Programmatic digital advertising, representing 60% of the digital segment, grew at a high single-digit rate in Q3, signaling strong organic growth potential.
- +7 more takeaways
Akebia Q3 2025 Earnings Call - Operational Hurdles Temper Strong Vafseo Launch and Clinical Promise
Akebia reported Q3 2025 revenues of $58.8 million, fueled primarily by $14.3 million in sales from Vafseo and continued strength in Auryxia. Despite Vafseo setting a high-water mark for dialysis thera...
- Vafseo generated $14.3 million in Q3 revenue with over 725 prescribers and more total prescriptions in 41 weeks than recent dialysis drugs.
- Vafseo prescribing access increased nearly 75%, from 40,000 to almost 70,000 patients, with key new provider additions including DaVita pilot and Innovative Renal Care (IRC).
- Operational challenges remain significant, slowing patient therapy starts and adherence in the dialysis setting where anemia treatment is highly protocolized.
- +12 more takeaways
Roivant Q2 2025 Earnings Call - Breakthrough Data Drives Transformative Pipeline Momentum
Roivant’s Q2 2025 earnings call showcased a company on the cusp of significant transformation, propelled by landmark data from brepocitinib in dermatomyositis (DM) and batoclimab in Graves’ disease. T...
- Valor phase 3 data for brepocitinib in dermatomyositis met all 10 ranked endpoints with robust, rapid, and clinically meaningful responses.
- NDA submission for brepocitinib in DM remains on track for first half of 2026, aiming to introduce the first novel oral DM therapy.
- Graves’ disease batoclimab durable remission data showed approximately 81% of followed patients remained responders after six months off drug, illustrating disease-modifying potential.
- +13 more takeaways
BARK Q2 FY2026 Earnings Call - Debt Free, Diversified Revenue, and Growing Margins Amid Tariff Headwinds
BARK reported a solid Q2 with $107 million revenue beating guidance and adjusted EBITDA slightly negative at $1.4 million, reflecting disciplined investment in growth. The company celebrated paying of...
- BARK is now debt-free after paying off its $45 million convertible note in cash, improving financial flexibility.
- Q2 revenue reached $107 million, exceeding guidance, with adjusted EBITDA of negative $1.4 million within expectations.
- Commerce segment revenue grew 6% year-over-year to $24.8 million, making up 24% of total revenue, its highest proportion ever.
- +12 more takeaways
Compugen Q3 2025 Earnings Call - Strategic Focus on FC-Reduced TIGIT Antibodies and Clinical Progress
Compugen's Q3 2025 call highlights a pivotal phase under new CEO Eran Ophir, emphasizing the company's unique position in computational drug discovery, particularly with FC-reduced anti-TIGIT antibodi...
- Compugen appointed Eran Ophir as new President and CEO, emphasizing his prior role as CSO and deep scientific involvement.
- Company differentiates its FC-reduced anti-TIGIT antibodies, notably COM902, from FC-active counterparts, highlighting efficacy and safety advantages.
- FC-active anti-TIGIT antibodies underperformed due to depletion of effector T cells and T regs, limiting both efficacy and safety.
- +11 more takeaways